Clinical Scorecard: FDA Approves Lilly’s Foundayo Oral GLP-1 Pill
At a Glance
Category
Detail
Condition
Obesity and overweight with weight-related medical conditions
Key Mechanisms
Oral glucagon-like peptide-1 (GLP-1) receptor agonist promoting weight loss and cardiometabolic risk reduction
Target Population
Adults with obesity or overweight, including those with type 2 diabetes
Care Setting
Outpatient management with prescription access via LillyDirect, retail pharmacies, and telehealth
Key Highlights
Orforglipron (Foundayo) is a once-daily oral GLP-1 receptor agonist approved for chronic weight management.
Phase 3 ATTAIN trials showed significant weight loss (up to 12.4% mean reduction) and improvements in cardiometabolic markers.
Safety warnings include risk of thyroid tumors; contraindicated in patients with medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.
Guideline-Based Recommendations
Diagnosis
Identify adults with obesity or overweight and weight-related comorbidities eligible for chronic weight management.
Management
Administer orforglipron once daily alongside reduced-calorie diet and increased physical activity.
Avoid use in patients with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.
Monitoring & Follow-up
Monitor for adverse events including gastrointestinal symptoms (nausea, diarrhea, constipation, vomiting).
Surveillance for thyroid-related adverse effects due to potential tumor risk.
Risks
Potential risk of thyroid tumors including thyroid cancer.
Common adverse events: nausea, diarrhea, constipation, vomiting.
Patient & Prescribing Data
Adults with obesity or overweight, with or without type 2 diabetes, requiring chronic weight management
Significant weight loss demonstrated in clinical trials; available via LillyDirect and retail with variable copay assistance programs.
Clinical Best Practices
Combine orforglipron therapy with lifestyle interventions including diet and exercise for optimal weight loss.
Screen patients for thyroid cancer risk factors before initiating therapy.
Educate patients on potential gastrointestinal side effects and monitor tolerability.
Utilize savings programs to improve patient access and adherence.
Mendelian randomization analyses linked higher birthweight with greater mid-childhood height but the connection could reflect genetic factors related to skeletal growth.
